DoH Policies screened during the period: 1st Jan 2019 – 31st March 2019
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA472 - Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
- NICE Technology Appraisal TA483 - Nivolumab for previously treated squamous non-small-cell lung cancer
- NICE Technology Appraisal TA484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer
- NICE Technology Appraisal TA487 - Venetoclax for treating chronic lymphocytic leukaemia
- NICE Technology Appraisal TA490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
- NICE Technology Appraisal TA491 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia
- NICE Technology Appraisal TA492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
- NICE Technology Appraisal TA505 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
- NICE Technology Appraisal TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
- NICE Technology Appraisal TA517 - Avelumab for treating metastatic Merkel cell carcinoma (update)
- NICE Technology Appraisal TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE Technology Appraisal TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
- NICE Technology Appraisal TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
- NICE Technology Appraisal TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
- NICE Technology Appraisal TA550 - Vandetanib for treating medullary thyroid cancer
- NICE Technology Appraisal TA551 - Lenvatinib for untreated advanced hepatocellular carcinoma
- NICE Technology Appraisal TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
- NICE Technology Appraisal TA555 - Regorafenib for previously treated advanced hepatocellular carcinoma (rapid review of TA514)
- NICE Technology Appraisal TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
- The Health Services (Cross-Border Health Care and Miscellaneous Amendments) (Northern Ireland) (EU Exit) Regulations 2019
- To control pregabalin and gabapentin under the Misuse of Drugs Act 1971 (MDA) and to schedule both medicines under the Misuse of Drugs Regulations (Northern Ireland) 2002 (MDRs)
- The Northern Ireland Social Care Council (Appointments and Procedure) (Amendment) Regulations (Northern Ireland) 2018
- Ophthalmic Uplift 2018/19
- The Health and Personal Social Services (Superannuation), and Health and Social Care Pension Scheme (Amendment) Regulations (Northern Ireland) 2019
- Provision of Health Services to Persons Not Ordinarily Resident (Amendment) (Northern Ireland) (EU Exit) Regulations 2019